This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
- Conditions
- Alzheimer's Disease PsychosisMedDRA version: 20.0Level: PTClassification code: 10012271Term: Dementia Alzheimer's type Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-507351-29-00
- Lead Sponsor
- Acadia Pharmaceuticals Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 752
Subject has successfully completed ACP-204-006 study, Male or female (age 55 to 85 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential, Subject has a designated study partner/caregiver, Subjects are able to complete all study visits with a study partner/caregiver, Signed inform consent form with a caregiver or legal representative
Requires treatment with a medication prohibited by the protocol, Is in hospice and receiving end-of-life palliative care, or has become bedridden, Female who is pregnant or breastfeeding, Unstable clinically significant medical condition other than AD, Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method